Challenges in Neurpathic Pain

Welcome to the sixth issue of Challenges in Neurpathic Pain, a newsletter brought to you by the members of the Multidisciplinary Panel on Neurpathic Pain. The Panel celebrates their second birthday in December 2003. Since its inception, the Panel has developed a wide range of projects, including recommendations on neurpathic pain, a patient information leaflet and poster, a certificate course on neurpathic pain and, of course, this newsletter.

In this issue, recommendations on the management of poststroke pain are presented, as well as an interesting case on acute transverse myelitis. Regular features, including a literature review, Q&A, useful Web sites and a calendar of upcoming conferences, will keep Hong Kong clinicians informed of the latest news on neurpathic pain.

RECOMMENDATIONS FOR THE MANAGEMENT OF POSTSTROKE KA PAIN

One of the key initiatives of the Multidisciplinary Panel on Neurpathic Pain is the development of treatment recommendations for a number of common neurpathic pain syndromes. The recommendations will better assist general practitioners to recognize the signs and symptoms of neurpathic pain, and to initiate appropriate treatment. In this issue, a summary of the recommendations for managing poststroke pain is presented. Dr Wong Chun Por was the project leader for these recommendations.

Pathophysiology, Prevalence and Symptoms

Several types of pain can occur following a stroke. Pain caused by stroke-related damage to the central nervous system is termed ‘central pain’. Pain may also arise from rigidity and reduced mobility, or from pre-existing conditions, such as osteoarthritis, which should be differentiated from central pain. Central poststroke pain (CPPS) is a neurpathic pain syndrome characterized by constant or intermittent pain following stroke. CPPS was initially termed ‘thalamic syndrome’, as the lesions caused by the stroke were thought to be located in the thalamus, but CPPS may also arise from extrathalamic lesions. Neocortical pain (eg, frozen shoulder) may also occur in CPPS patients.

The incidence of CPPS has been reported at 8%, with moderate-to-severe pain reported by 5% of all stroke patients. The onset of pain occurs within 1 month in over half of all CPPS patients; however, in some patients, CPPS can take more than 6 months to develop. CPPS tends to affect younger stroke patients. Typical symptoms of CPPS are outlined in Figure 1. Pain may be unilateral, or it may only affect small areas. Pain intensity may also vary within the affected area. Furthermore, symptoms can be exacerbated by stress and reduced by relaxation.

Figure 2: Differentiating central poststroke pain from nociceptive pain

• Test sensation to sharp and blunt objects
• Test the sensation to warmth (eg, touch with a finger) and coolness

Table: Typical symptoms of central poststroke pain

This table highlights the differences between neurpathic pain and nociceptive pain.

Figure 1: Typical symptoms of central poststroke pain

In this issue, recommendations on the management of poststroke pain are presented, as well as an interesting case on acute transverse myelitis. Regular features, including a literature review, Q&A, useful Web sites and a calendar of upcoming conferences, will keep Hong Kong clinicians informed of the latest news on neurpathic pain.

Web sites on neuropathic pain

Various Web sites are devoted to neuropathic pain or pain management and provide useful information for clinicians and patients.

The International Research Foundation for Reflex Sympathetic Dystrophy/Complex Regional Pain Syndrome (www.rfirf.org) is dedicated to research and education on reflex sympathetic dystrophy (RSD), which is also known as complex regional pain syndrome (CRPS). The site provides practice guidelines for clinicians and a video on the impact of this chronic neurological condition in children.

The Pain Relief Foundation (www.painrelieffoundation.org.uk) is a charity in the UK that funds research on chronic pain and promotes education on pain management. The site provides an overview of a range of painful disorders, including neuropathic pain syndromes such as postherpetic neuralgia, trigeminal neuralgia, CRPS/RSD and phantom limb pain, and links to other Web sites for further information on each of the conditions.

CONFERENCE CALENDAR


CO N T A C T D E T A I L S

Contact: Conference Secretariat, DC Conferences Pty Ltd, PO Box 571, Crowes Nest NSW 1585, Australia.
Tel: (+61 2) 9554 4000 Fax: (+61 2) 9554 4666 E-mail: APS2004@coconferences.com.au
Website: www.painrelieffoundation.org.au

Table of contents

1. Challenges in Neurpathic Pain
2. Pathophysiology, Prevalence and Symptoms
3. Recommendations for the Management of Poststroke Pain
4. Web sites on neuropathic pain
5. Conference calendar

WEB SITES ON NEUROPATHIC PAIN

The site provides practice guidelines for clinicians and a video on the impact of this chronic neurological condition in children.

The Pain Relief Foundation (www.painrelieffoundation.org.uk) is a charity in the UK that funds research on chronic pain and promotes education on pain management. The site provides an overview of a range of painful disorders, including neuropathic pain syndromes such as postherpetic neuralgia, trigeminal neuralgia, CRPS/RSD and phantom limb pain, and links to other Web sites for further information on each of the conditions.

Web sites on neuropathic pain

Various Web sites are devoted to neuropathic pain or pain management and provide useful information for clinicians and patients.

The International Research Foundation for Reflex Sympathetic Dystrophy/Complex Regional Pain Syndrome (www.rfirf.org) is dedicated to research and education on reflex sympathetic dystrophy (RSD), which is also known as complex regional pain syndrome (CRPS). The site provides practice guidelines for clinicians and a video on the impact of this chronic neurological condition in children.

The Pain Relief Foundation (www.painrelieffoundation.org.uk) is a charity in the UK that funds research on chronic pain and promotes education on pain management. The site provides an overview of a range of painful disorders, including neuropathic pain syndromes such as postherpetic neuralgia, trigeminal neuralgia, CRPS/RSD and phantom limb pain, and links to other Web sites for further information on each of the conditions.

PANEL MEMBERS

- Dr Chan Pheon Ping, Consultant, Department of Anaesthesiology, Intensive Care & Operating Services, Prince of Wales Hospital, Kowloon.
- Dr Joseph Ip, Chief of Division of Hand & Foot Surgery, Department of Orthopaedic Surgery, The Chinese University of Hong Kong.
- Dr David LAM, Consultant, Division of Neurosurgery, Prince of Wales Hospital.
- Dr Lee Tung Woon, Consultant, Department of Anaesthesiology & Intensive Care, Tuen Mun Hospital.
- Dr Tsoi Tak Hong, Consultant, Department of Anaesthesiology & Intensive Care, Tuen Mun Hospital.
- Dr Cheung Pak Wah, Consultant, Department of Anaesthesiology, Intensive Care & Operating Services, Prince of Wales Hospital.
- Dr Lawrence KS Wong, Consultant, Department of Neurology, Prince of Wales Hospital, Kowloon.
- Dr Wong Chun Por, Consultant, Department of Anaesthesiology & Intensive Care, Tuen Mun Hospital.
- Dr Josephine Ip, Consultant, Department of Orthopaedic Surgery, The Chinese University of Hong Kong.
- Dr Carol Lee, Consultant, Department of Anaesthesiology & Intensive Care, Tuen Mun Hospital.

The Federation of Medical Societies of Australia (FMSA) is the peak body for the medical profession in Australia. The FMSA is an organization that represents over 70,000 medical practitioners across Australia.

The Australian Medical Association (AMA) is the largest professional association of medical practitioners in Australia. The AMA is an organization that represents over 80,000 medical practitioners across Australia.

The Royal Australasian College of Physicians (RACP) is a professional association of medical practitioners in Australia. The RACP is an organization that represents over 60,000 medical practitioners across Australia.

The Australian Medical Council (AMC) is an independent, not-for-profit organization that ensures that medical practitioners in Australia are fit to practise medicine. The AMC is an organization that represents over 60,000 medical practitioners across Australia.
Diagnosis
Because the onset of CPSP can occur several months after a stroke, primary-care physicians involved in poststroke care and responsible for follow-up must be alert to the possible development of pain. All stroke patients reporting pain should be assessed for CPSP. Techniques for differentiating CPSP from nociceptive pain are described in Figure 2.

General Management of Poststroke Pain

Nociceptive pain

1. Differentiate nociceptive pain from CPSP, and treat nociceptive pain appropriately.
2. Nociceptive pain (such as frozen shoulder) should be treated with analgesic agents (eg, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors or opioids), intraarticular injection and physiotherapy. Physiotherapy should be commenced as soon as possible after a stroke.

Central poststroke pain

1. Record the CPSP baseline (or pretreatment) pain intensity to allow comparison with posttreatment pain. A visual analog scale (VAS) is one of the simplest means of assessing pain. Patients rate their pain on a scale from 0 mm (no pain) to 100 mm (excruciating pain).
2. Counsel patients in relaxation techniques, as stress can exacerbate pain.
3. Commence treatment with a tricyclic antidepressant (TCA), such as amitriptyline, as a first-line agent. Lamotrigine can be considered as an alternative first-line agent. Gabapentin may also be effective in CPSP. If pain relief is unsatisfactory with first-line agents, oxycodone may be used as an adjunct. Early treatment improves outcomes for CPSP patients. Conventional analgesics, including opioids, tend not to be effective in treating CPSP.
4. Consider referral to a multidisciplinary pain centre if a patient remains refractory to pharmacotherapy after 2 to 3 months of treatment.

Pharmacological and Nonpharmacological Treatment of CPSP

Relatively few clinical trials have investigated the treatment of CPSP. TCAs or other anti-inflammatories are the usual first-line treatments. Pharmacological management should be supplemented with physical and psychological interventions.

Recommendations for pharmacological treatments are based on published clinical evidence and current clinical practice; however, some of the agents may not be approved for use in neuropathic pain syndromes. Clinicians should consult local prescribing information before initiating treatment.

1. Amitriptyline controls pain in CPSP patients more effectively than carbamazepine and is better tolerated. TCAs, such as amitriptyline or nortriptyline, should be considered as first-line therapy. To minimize side effects, patients should begin with a low dose and titrate to a higher maintenance dose. In elderly patients, amitriptyline or nortriptyline should be commenced at 25 mg daily and titrated to 75 mg daily, or the maximum tolerated dose. In frail or very elderly patients who are at risk of sedation by TCAs, consider a lower starting dose of amitriptyline (eg, 10 mg daily).

2. Lamotrigine is an alternative first-line treatment. Lamotrigine should be titrated from 25 mg daily to a maximum dose of 200 mg daily, or the maximum tolerated dose. However, a rare, but potentially life-threatening, complication of lamotrigine is Stevens-Johnson syndrome.

3. Gabapentin is approved for the treatment of neuropathic pain and may be effective in treating CPSP. Gabapentin should be commenced at 300 mg at bedtime and increased by 300 mg every 3 days up to a dose of 1,800 mg daily after 1 week (given in 3 divided doses). If higher daily doses are required for maintenance, the maximum recommended dose is 3,600 mg daily (a lower dose is recommended in patients with renal impairment). For elderly patients or patients sensitive to side effects, the recommendation is to increase the gabapentin dosage by 300 mg every week, or to begin with a lower dose (eg, 100 mg).

4. Mexiletine is an antiarrhythmic agent and may be used as an adjunct to TCAs when patients do not respond to TCAs alone.

5. Intraarticular lignocaine may provide pain relief in some patients.

6. Surgical interventions can be considered for patients unresponsive to pharmacological therapy; however, these treatments have associated morbidity and mortality. Precentral cortex stimulation, spinal cord stimulation and stereotactic mesencephalic tractotomy may benefit selected CPSP patients.

Clinical Examination

Physical examination upon admission showed that the patient was fully conscious with normal cognitive function. All cranial nerves were intact. Motor function, gait, proprioception, temperature and touch was found on the left side of his body below the T1 level. The patient's left hand and medial aspect of the left arm were also affected. Vibration and proprioception sensations were intact in all limbs. The tone in both upper limbs was mildly increased. All tendon reflexes were normal and the plantar response was flexor on both sides. There was minimal weakness in his left-sided limbs. The Romberg test was negative and his gait was normal. A noncontrast computed tomography brain scan was normal on the day of admission.

Over the next 2 days, the patient complained that the abnormal sensations were becoming more unpleasant and had spread to the right side of his body. A magnetic resonance imaging (MRI) scan of the spine showed a T2 hyperintense signal, with gadolinium enhancement of the spinal cord from level C2 to T2-C3, revealed mild cord expansion (Figure 4). Brain MRI, cerebrospinal fluid and blood tests were unremarkable.

Interpretation

Typical clinical features of complete spinal cord syndrome include symmetric motor, sensory and sphincter dysfunction below the level of the lesion. Incomplete spinal cord syndrome is frequently encountered, particularly in the case of myelitis. Sensory symptoms include neuropathic pain, which may be asymmetric and can be the dominant presenting feature, as illustrated in this case. The level of sensory symptoms is an important clue to determine the location of the underlying spinal cord lesion.

Management

After the identification of transverse myelitis, adequate work-up to identify any underlying associated disease, such as infection, connective tissue disease and vasculitis, is required to delineate the exact diagnosis. This has important implications for subsequent management. The diagnosis in this case was idiopathic acute transverse myelitis, though transverse myelitis can be caused by multiple sclerosis. The patient was treated with intravenous pulse methylprednisolone (3 g daily for 3 consecutive days). Motor function recovered rapidly, but the patient still had troublesome dysesthesia on his left side. The neuropathic pain responded well to a combination of amitriptyline and carbamazepine. The patient returned to work soon after discharge and within 2 weeks of the onset of symptoms. A follow-up MRI several months later showed complete resolution of the spinal cord abnormalities.

Q&A

Readers are encouraged to send questions to members of the Multidisciplinary Panel on Neuropathic Pain. Please forward your questions concerning any aspect of neuropathic pain and its management to mpn@medimedia.com.au or fax to (+613) 2559 6510.

Is sciatica a type of neuropathic pain?

Sciatica, a common cause of low back pain, is a type of neuropathic pain that occurs when the sciatic nerve or lumbar root nerves are compressed. It is often accompanied by pain radiating from the back into the buttock and, sometimes, down the entire leg. Common symptoms of sciatica include changes in sensation in the calf muscle or foot, pain, paresthesia and numbness. Some patients may have difficulty walking. Conservative treatment involves physiotherapy, hot packs and manipulation, and is often an appropriate treatment approach as sciatica can resolve on its own with time. Patients should be instructed to try to maintain mobility. Other treatment options include oral NSAIIDs, gabapentin (see Literature Review), epidural corticosteroid injections, percutaneous and transcutaneous electrical nerve stimulation, chemoneurolysis and surgical interventions, such as disectomy.